Nuwellis Q2 Revenue Up 14%, Gross Margin Jumps to 76%, Cash Runway Extended to Q2 2027
NUWE is trading near its 52-week low of $1.25 (7.2% above the low) on light trading volume (0.2× avg).
Summary
Nuwellis reported strong Q2 2026 results with 14% revenue growth and a 20-point gross margin improvement, while post-quarter financing extended its cash runway to Q2 2027.
Key Events · Earnings and Guidance · NUWE
-
Q2 Revenue Up 14%
Net sales reached $2.0 million in Q2 2026, a 14% increase from $1.7 million in the prior-year quarter. U.S. revenue grew 17%.
-
Gross Margin Expands to 76%
Gross margin improved to 76% from 56% a year ago, driven by pricing adjustments, favorable product mix, and the transition to contract manufacturing.
-
Cash Runway Extended to Q2 2027
Subsequent to June 30, 2026, the company raised approximately $6.7 million from a July financing and warrant exercises, extending its cash runway through the second quarter of 2027.
-
FDA Pre-Submission Meeting Successful
Nuwellis advanced its proposed Aquadex label expansion to patients weighing 5 kilograms or more, following a successful FDA pre-submission meeting.
Analysis · NUWE · Industrial Applications And Services
Nuwellis reported Q2 2026 revenue of $2.0 million, up 14% year-over-year, with gross margin improving to 76% from 56%. The company raised $6.7 million after quarter-end, extending its cash runway through the second quarter of 2027. The results show meaningful commercial progress and a strengthened balance sheet, though the company remains unprofitable with a net loss of $4.8 million.
At the time of this filing, NUWE was trading at $1.34 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $1.25 to $235.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.